Mahesh Percy¹*, Ronne Joseph² and Ewarld Marshall³

¹Instructor/Medical Technologist, Medical Pathology Diagnostic Laboratory, St. George’ s University, Grenada
²Clinical Instructor, St. George’ s University, Grenada
³Chair, Pathology, Director, Medical Pathology Diagnostic Laboratory, St. George’ s University, Grenada

*Corresponding Author: Mahesh Percy, Instructor/Medical Technologist, Medical Pathology Diagnostic Laboratory, St. George’ s University, Grenada.

Received: February 13, 2024; Published: April 02, 2024

Abstract

Myelodysplastic syndrome (MDS) is a group of blood cancer which interfere with the body's ability to produce normal healthy blood cells. It was once thought to be a rare disorder, now recognized as the common hematologic neoplasm affecting more than 30,000 persons per year in the United States. This disease affects mostly the elderly population and men are more commonly affected than women [1,14]. The etiology of MDS is unknown. Here we present a 88 year old women with dysplasia of two cell (erythroid and myeloid) lineages. The patient is slightly anemic and has macrocytosis. This hematologic disorder is characterized by cytopenia and dysplasia in one or more cell lineage [2,11]. The patient's medical history revealed a gradual onset of fatigue, weakness, and increased susceptibility to infections. Diagnostic investigations, including peripheral blood smear, unveiled dysplastic changes across various cell lines, indicative of MDS. The diagnosis and classification are with the findings of dysplasia in one or more cell linage and blast cells in the bone marrow [3]. It is essential to do bone marrow aspiration and cytogenetics to come to a final diagnosis. Given the patient’s advanced age, the patient refused to do bone marrow aspiration or cytogenetics. The primary purpose of this article on myelodysplastic syndrome (MDS) is to provide a comprehensive understanding of the disease, aiming to enhance diagnosis and knowledge.

Keywords: Myelodysplastic Syndrome (MDS); Acute Myeloid Leukemia (AML)

References

1. Alessandrino EP., et al. “Myelodysplastic syndromes: recent advances”. Haematologica (2001): 861124115711694400.
2. Tefferi A and Vardiman JW. “Myelodysplastic syndromes”. The New England Journal of Medicine 19 (2009): 1872-1885.
3. Germing U., et al. “Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients”. Leukemia Research 24 (2003): 983-992.
4. Rollison DE., et al. “Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States 2001-2004, using data from the NAACCR and SEER programs”. Blood (2008): 112455218443215.
5. Hellström-Lindberg E., et al. “Achievements in understanding and treatment of myelodysplastic syndromes”. American Society of Hematology Education Program Book (2000): 11013211701538.
6. Greenberg P., et al. “International scoring system for evaluating prognosis in myelodysplastic syndromes”. Blood 89 (1977): 2079-2088.
7. Bernasconi P., et al. “World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes”. British Journal of Haematology3 (2007): 193-205.
8. Niscola P., et al. “Managing myelodysplastic syndromes in very old patients: a teaching case report”. Clinical Interventions in Aging 8 (2013): 391-394.
9. Cheson BD. “The myelodysplastic syndromes: current approaches to therapy”. Annals of Internal Medicine (1990): 1129329412187393.
10. Ria R., et al. “Managing myelodysplastic symptoms in eldery patients”. Clinical Interventions in Aging 4 (2009): 413-423.
11. Ma X., et al. “Myelodysplastic syndromes”. Cancer8 (2007): 1536-1542.
12. Stauder R. “The challenge of individualized risk assessment and therapy planning in eldery high-risk myelodysplastic syndromes (MDS) patients”. Annals of Hematology9 (2012): 1333-1343.
13. Schumacher HR and Nand S. “Myelodysplastic Syndromes: Approach to Diagnosis and Treatment”. New York: Igaku-Shoin Medical Publishers; (1995).
14. Cazzola M, Malcovati L. “Myelodysplastic syndromes—coping with ineffective hematopoiesis”. The New England Journal of Medicine 352 (2005): 536-538.
15. Bennett J. “The myelodysplastic syndromes: pathobiology and clinical management”. In: B Cheson, editor Basic and Clinical Oncology, vol. 27 New York: Marcel Dekker; (2002): 3-7.

Citation

Citation: Mahesh Percy., et al. “A Case Report on Myelodysplastic Syndrome with the Dysplasia of Two Cell Lineage".Acta Scientific Clinical Case Reports 5.5 (2024): 03-06.

Copyright

Copyright: © 2024 Mahesh Percy., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.